H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001410578-22-001133 Act: 34 Size: 5 MB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-053640 Act: 34 Size: 240 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-052375 Act: 34 Size: 244 KB 网页链接
$Cytosorbents(CTSO)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001033475-22-000004 Act: 34 Size: 19 KB 网页链接
$Cytosorbents(CTSO)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-22-049017 Act: 34 Size: 3 MB 网页链接
$Cytosorbents(CTSO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-22-049027 Act: 34 Size: 4 MB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-046026 Act: 34 Size: 277 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-043652 Act: 34 Size: 250 KB 网页链接
$Cytosorbents(CTSO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001104659-22-042910 Size: 13 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-042913 Size: 7 KB 网页链接